Jazz Pharmaceuticals (Nasdaq: JAZZ ) is expected to report Q3 earnings on Nov. 8. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals's revenues will grow 143.6% and EPS will grow 57.8%.
The average estimate for revenue is $178.6 million. On the bottom line, the average EPS estimate is $1.31.
Last quarter, Jazz Pharmaceuticals notched revenue of $129.5 million. GAAP reported sales were much higher than the prior-year quarter's $64.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.09. GAAP EPS of $0.45 for Q2 were 37% lower than the prior-year quarter's $0.71 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 90.3%, 450 basis points worse than the prior-year quarter. Operating margin was 37.7%, 1,470 basis points worse than the prior-year quarter. Net margin was 21.0%, 3,040 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $611.8 million. The average EPS estimate is $4.77.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 210 members out of 276 rating the stock outperform, and 66 members rating it underperform. Among 69 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give Jazz Pharmaceuticals a green thumbs-up, and 21 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals is buy, with an average price target of $65.63.
- Add Jazz Pharmaceuticals to My Watchlist.